Ruolo della farmacogenetica nella identificazione della migliore strategia terapeutica per il paziente affetto da carcinoma polmonare non a piccole cellule

Translated title of the contribution: Role of pharmacogenetics in choosing the best therapeutic strategy for non-small cell lung cancer patients

Katia Danza, Daniela Petriella, Domenico Galetta, Ettore Fistola, Rosamaria Pinto, Brunella Pilato, Marianna Martinucci, Massimo Bonucci, Stefania Tommasi, Gianmauro Numico, Nicola Silvestris

Research output: Contribution to journalArticlepeer-review

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in many countries. The carcinogenesis of this malignancy is characterized by different genetic and epigenetic alterations. Knowledge of the signal transduction pathways specific to neoplastic cells has recently led to the development of a targeted approach, called "target therapy". The aim of this therapeutic strategy is to single out small molecules or monoclonal antibodies directed against molecular targets. Recent findings have revealed EGFR mutations in lung cancer cells and have shown their predictive role in the response to EGFR Tyrosine Kinase Inhibitors (EGFR-TKI). These pharmacogenetic approach studies have allowed patients who might benefit from a specific antineoplastic treatment to be selected without the risk of useless severe toxicity.

Translated title of the contributionRole of pharmacogenetics in choosing the best therapeutic strategy for non-small cell lung cancer patients
Original languageItalian
Pages (from-to)187-193
Number of pages7
JournalTrends in Medicine
Volume9
Issue number4
Publication statusPublished - Oct 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Role of pharmacogenetics in choosing the best therapeutic strategy for non-small cell lung cancer patients'. Together they form a unique fingerprint.

Cite this